ProRx Pharma has announced the addition of six injectable products to its portfolio, aimed at supporting the growing demand ...

For the fiscal year 2025, Hikma has reiterated its guidance, expecting group revenue to grow between 4% and 6%, with core operating profit projected to be in the range of $730 million to $770 million.